Last reviewed · How we verify
NCT07343479
Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases
Phase 2 trial testing sac-TMT plus EGFR-TKI in NSCLC (Advanced Non-small Cell Lung Cancer) in 45 participants. Not yet recruiting.
20 June 2027
Quick facts
| Lead sponsor | Zhejiang Cancer Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 45 |
| Start date | 1 May 2026 |
| Primary completion | 20 June 2027 |
| Estimated completion | 20 December 2029 |
| Sites | 1 location across China |
Drugs / interventions tested
- sac-TMT plus EGFR-TKI — full drug profile →
Conditions studied
- NSCLC (Advanced Non-small Cell Lung Cancer) — all drugs for NSCLC (Advanced Non-small Cell Lung Cancer) →
- EGFR Gene Mutations — all drugs for EGFR Gene Mutations →
- Brain Metastasis — all drugs for Brain Metastasis →
Sponsor
Zhejiang Cancer Hospital
Who can join
Adults 18 to 75, any sex, with NSCLC (Advanced Non-small Cell Lung Cancer) or EGFR Gene Mutations. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective, open-label, multi-center, single-arm clinical trial
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07343479
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for NSCLC (Advanced Non-small Cell Lung Cancer)
Currently open trials in the same condition.
- NCT07528274 — Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure · Phase 2 · recruiting
- NCT07348965 — Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis · NA · recruiting
- NCT07478809 — A Retrospective Real-World Study Based on RATIONALE-307 · recruiting
- NCT07361237 — A Phase l Clinical Study to Evalute the Safety,Tolerability,Pharmacokinetic Characteristics,and Preliminary Anti-tumor E · Phase 1 · recruiting
- NCT07371663 — An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
Other Zhejiang Cancer Hospital trials
Trials by the same sponsor.
- NCT07441720 — Safety and Efficacy of Umbilical Cord Blood Therapy for Cancer Therapy-Induced Thrombocytopenia (CTIT) · Phase 2 · recruiting
- NCT07416890 — Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Ref · Phase 2 · recruiting
- NCT07326150 — Construction of a Predictive Model for the Efficacy of Chemoprevention Combined With Targeted Therapy in Pancreatic Canc · active not recruiting
- NCT07330544 — A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Rec · Phase 2 · recruiting
- NCT07235930 — Firstline Sequential AG and mFOLFOX Combined With Serplulimab and Bevacizumab Versus AG Chemotherapy Alone in Advanced P · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07343479 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zhejiang Cancer Hospital
- Last refreshed: 15 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07343479.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing